Probenecid Inhibits Respiratory Syncytial Virus (RSV) Replication.

Murray, Jackelyn; Bergeron, Harrison C; Jones, Les P; Reener, Zachary Beau; Martin, David E; Sancilio, Fred D; Tripp, Ralph A

Murray, Jackelyn; Bergeron, Harrison C; Jones, Les P; Reener, Zachary Beau; Martin, David E; Sancilio, Fred D; Tripp, Ralph A.

Afiliación

Murray J; Department of Infectious Diseases, University of Georgia, Athens, GA 30602, USA.
Bergeron HC; Department of Infectious Diseases, University of Georgia, Athens, GA 30602, USA.
Jones LP; Department of Infectious Diseases, University of Georgia, Athens, GA 30602, USA.
Reener ZB; Department of Infectious Diseases, University of Georgia, Athens, GA 30602, USA.
Martin DE; TrippBio, Inc., Jacksonville, FL 32256, USA.
Sancilio FD; Department of Chemistry and Biochemistry, Florida Atlantic University, Jupiter, FL 33431, USA.
Tripp RA; Department of Infectious Diseases, University of Georgia, Athens, GA 30602, USA.

Viruses ; 14(5)2022 04 27.

Article en En | MEDLINE | ID: mdl-35632652

Asunto(s)

COVID-19; Infecciones por Virus Sincitial Respiratorio; Virus Sincitial Respiratorio Humano; Animales; Ratones; Probenecid/farmacología; Probenecid/uso terapéutico; Infecciones por Virus Sincitial Respiratorio/tratamiento farmacológico; Infecciones por Virus Sincitial Respiratorio/metabolismo; Infecciones por Virus Sincitial Respiratorio/prevención & control; Virus Sincitial Respiratorio Humano/genética; SARS-CoV-2; Replicación Viral

Palabras clave

antiviral; prophylactic; respiratory syncytial virus (RSV); therapeutic

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Virus Sincitial Respiratorio Humano / Infecciones por Virus Sincitial Respiratorio / COVID-19 Límite: Animals Idioma: En Revista: Viruses Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google